Why the study?
Does high-dose neuroleptic treatment improve clinical outcomes or increase adverse reactions compared to low-dose treatment in patients with chronic psychosis?
Does high-dose neuroleptic treatment improve clinical outcomes or increase adverse reactions compared to low-dose treatment in patients with chronic psychosis?
Answers are grounded in this paper and cite their sources.
In patients with chronic psychosis, neuroleptic doses above 375 mg chlorpromazine equivalent provide no additional clinical benefit but significantly increase adverse reactions.
Effectiveness and side-effects of high- versus low-dose neuroleptic treatment of chronic psychosis have been assessed through a meta-analysis of 22 published randomized control trials comparing different neuroleptic doses. No incremental clinical improvement was found at doses above 375 mg equivalent of chlorpromazine, while a significant increase in adverse reactions was observed.
No takes yet. Share an insight, caveat, or question.
Bollini et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: